NCT02871323View on ClinicalTrials.gov

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2016

Primary Completion Date

November 30, 2016

Conditions
Polycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary Myelofibrosis
Interventions
BIOLOGICAL

Durvalumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

The Leukemia and Lymphoma Society

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER